Home » Posts tagged 'award'
Tag Archives: award
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....FOR BLOG HOME CLICK HEREFlag and hits
ORGANIC SPECTROSCOPY
SUBSCRIBE
Subscribe in a reader
Enter your email address:
Delivered by FeedBurner
Subscribe to New Drug Approvals by Email
Personal Links
- my sites on the net
- DR ANTHONY MELVIN CRASTO
- GOOGLE GROUP ORGANIC PROCESS DEVELOPMENT
- mixxt
- epernicus
- scipeople
- jimdo
- yolasite
- my cv
- slidestaxx
- wordpress blog
- ABOUT ME
- BRANDSITE
- SKILLPAGES
- Academia.edu
- DIIGO
- WIX
- WIX BLOG
- ISSUU
- SCRIBD
- BIZ
- GOOGLE BLOG
- APNACIRCLE
- Eurekamoments in Organic Chemistry
- Organic Chemistry by Dr Anthony
- Green Chemistry International
- Technology Transfer
- Stereochemistry
- Spectroscopy
- Polymorphism
- Reactions in Org Chem
- DR ANTHONY MELVIN CRASTO Ph.D
- Pharmaceuticals
- Medicinal chemistry
- Organic chemistry literature
- Patent related site
- Green chemistry
- Reagents
- R & D
- Molecules
- Heterocyclic chem
- Sourcing
- NEW DRUG APPROVALS
- WORLD DRUG TRACKER
- Green Chemistry International
- drug regulatory affairs international
- ORGANIC SPECTROSCOPY INTERNATIONAL
- ORGANIC SYNTHESIS INTERNATIONAL
- ALL ABOUT DRUGS
- ORGANIC CHEMISTRY INTERNATIONAL
- GOOGLE PLUS
- Drug Scaleup and Manufacturing International
- MEDICINAL CHEMISTRY INTERNATIONAL
- DRUG SYNTHESIS INTERNATIONAL
- SLIDESHARE
- DRUGS WEB
- GOOGLE SCHOLAR
- MEDCHEM-amcrasto
- ONE ORGANIC CHEMISTONE DAY
- DRUG PATENTS INTERNATIONAL
- MEDCHEM ANTHONY CRASTO
- MEDCHEM anthony crasto
- Gravatar
- ZING ME VIETNAM
- RESEARCH GATE
- AWARDS
Verified Services
Anthony Crasto conferred ABPnews award for “Outstanding contribution to Education Sector”
Conferred prestigious award at event ABP News Presents Healthcare Leadership Awards 26th November, 2018 at Taj Lands End, Mumbai India
Dedicated to Shobha Crasto Aishal crasto Lionel crasto
Service to education is service to humanity
Society recognises efforts done towards it
/////////////award, event ABP News, Healthcare, Leadership, 26th, November, 2018, Taj Lands End, Mumbai, India, education, anthony crasto
ANTHONY M CRASTO GETS PHARMA EXCELLENCE AWARD AT THE GOLDEN GLOBE TIGER AWARDS 2018
Pic…. Shobha crasto, Lionel and Aishal collecting my award named The Golden Globe Tigers Awards 2018, for Excellence in Pharma, at kuala lumpur, Malaysia, 23 april 2018 at Pullman city centre hotel, Kuala lumpur, Malaysia. Dr Anthony could not travel as he is wheelchair bound and 90 percent paralysed
DR ANTHONY M CRASTO
The Golden Globe Tigers Award 2018 is the highest recognition amongst individual and organizations who have achieved the highest levels of standards and benchmark in numerous areas such as CSR, Pharma, Social Media & Digital Marketing, Education Leadership Award and so on. The award ceremony took place in Pullman Kuala Lumpur City Centre Hotel & Residences on the 23rd of April, where a number of respectable attendees were present not only from Malaysia but from many different parts of the world such as Iceland, Saudi Arabia, India, China, South Africa and such!
The Golden Globe Tigers Award not only aims to increase awareness on CSR practices but also continuously innovate practices towards sustainable development. It is organized by the founder of the World CSR Day, World Sustainability Congress and World Women Leadership Congress.
Dr. Anthony Melvin Crasto, graduated from Mumbai University, Completed his Ph.D from ICT, 1991, Mumbai, India, in the field of Organic Chemistry, Currently he is working with GLENMARK PHARMACEUTICALS LTD, Research Centre as a Principal Scientist, in Process Research at Mahape, Navi Mumbai, India, for the last 10 years, His total Industry experience is 30 +yrs with major Multinationals companies.
Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable Scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri , Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did Custom Synthesis for various multinationals in his career like BASF, Novartis, Sanofi, Pfizer etc., He has worked in Drug Discovery, Natural products, Bulk Drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, Pharma Plant, API plant etc, he is now helping millions, His friends call him worlddrugtracker.
His New Drug Approvals, All about drugs, Eurekamoments, Organic spectroscopy international, etc in Organic/ Medchem are some most read blogs. He has hands on experience in initiation and developing Novel routes for Drug molecules and implementing them on commercial scale over a 30 year tenure till date Feb’ 2018, Around 30 plus commercial products in his career. He has good knowledge of IPM, GMP, QbD, Regulatory aspects, Technology transfer, Manufacturing, Formulations, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc. He has several International patents published worldwide.
He suffered a one in a million disease in the form of a paralytic stroke/ Acute Transverse Mylitis in Dec’ 2007 and is 90 % paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, he has several million hits on Google, 60 Lakh plus views on dozen plus blogs, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto
He is a prolific presenter and is invited to major conferences in Mumbai, where he can travel easily. He speaks at universities on topics of Drug discovery, Patents, Qbd, GMP, Tech transfer, polymorphism, Literature search tools, Computer programs and Topics of interest to Pharma Students.
His extraordinary skill on the Computers give him the edge to write/present his thoughts. He demonstrates them to students and professionals alike.
Notably he has 20 lakh plus views on New Drug Approvals Blog in 216 countries, This blog has 3.5 lakh viewers in USA alone.
AWARDS
“100 Most Impactful Health care Leaders Global listing”, conferred at Taj lands end, Mumbai, India on 14 Feb 2014 by World Health Wellness congress and awards
“Best Worlddrugtracker “ Award for lifetime acheivement in Pharma… 7 th July 2017 , The venue…Taj land ends, Bandra, Mumbai India
“Lifetime achievement award” WORLD HEALTH CONGRESS 2017 in Hyderabad, 22 aug 2017 at JNTUH KUKATPALLY. HYDERABAD, TELANGANA, INDIA,
” Lifetime Achievement Award”, at the The Middle East Healthcare Leadership Awards – 12th October, 2017 -The Address, Dubai Mall, Dubai…UAE……….Mohammed Bin Rashid Boulevard, Downtown Dubai – Dubai – United Arab Emirates
International award for Outstanding contribution in Pharma at World Health and wellness Congress award, 14th Feb, 2018, at Taj Lands ends, Bandra, Mumbai, India
Conferred very prestigious IDMA award for contribution to society in Pharma at INDIAN DRUGS ANNUAL DAY 2018 VMCC IITBombay Powai, Mumbai India 22 Feb 2018,I was Guest of honor at and was felicitated by president,Indian Drug manufacturers association (IDMA)
The Golden Globe Tigers Awards 2018, for Excellence in Pharma, at kuala lumpur, Malaysia, 23 april 2018 at Pullman hotel.
Biography
READ MY BIOGRAPHY……….http://scijourno.com/2017/01/09/dr-anthony-crasto/ Written by Mr. Amrit B. Karmarkar
Director, InClinition
///////////////
Award for me, 100 Most Impactful Health care Leaders, Global listing
At award function for my award “100 Most Impactful Health care Leaders Global listing”, conferred on me at Taj lands end, Mumbai, India on 14 Feb 2014 by World Health Wellness congress and awards
Award for me, 100 Most Impactful Health care Leaders Global listing
At award function for my award “100 Most Impactful Health care Leaders Global listing”, conferred on me at Taj lands end, Mumbai, India on 14 Feb 2014 by World Health Wellness congress and awards
Fortune India presents award to Ajanta pharma
Fortune India has published list of 500 mid-size companies who ranked them on various parameters based on the results of 2013-2014. Ajanta pharma features very prominently in the lists. Ajanta’s ranking on various pararmeters is given below:
Ranked 3’d largest Wealth Creator on 5 year CAGR 93.14%
Ranked 10th on Capital Employed (ROCE)
Ranked 21st in Net profit .
Ranked 182nd in Sales
On 17’th August 2015, Fortune India organized an award function to present the awards to Top 10 largest weatth creator companies and Ajanta is one of those elite companies.
The awards were presented by Mr. Piyush Goyal, Minister of State-Power,Coal& New and Renewable Energy, Govt. of India to Mr. yogesh Agrawal, Managing Director and Mr.Rajesh Agrawal,Jt.Managing Director of the company.
Ajanta Pharma, “One of the Giants of Tomorrow” – Fortune India
We are pleased to share with you that Ajanta Pharma has been honoured as “ONE OF THE GIANTS OF TOMORROW” by prestigious Fortune India magazine on 19th August 2016 at New Delhi.
The honour was conferred to our Managing Director, Mr. Yogesh Agrawal and our Jt. Managing Director, Mr. Rajesh Agrawal at the hands of Hon. Mr. Nitin Gadkari, Union Minister for Road Transport and Highways and Shipping, Govt of India. This is the 2nd year in row where Ajanta has received the recognition from Fortune India.
Fortune India (June 2016 Issue) published the list of mid-size companies based on the financial year 2014-15 results and we are pleased to share with you that Ajanta has been ranked 3rd Top Wealth creator over last 5 years.
Ajanta Pharma Limited (APL) is a pharmaceutical company headquartered in Mumbai, India. It has strong presence in Branded Generic business in India & Emerging markets; and Generic business in USA. In India, company operates in selected therapeutic areas of Cardiology, Dermatology, Ophthalmology and Pain management. Its brands in each of sub-therapeutic areas or molecules hold leadership positions. In Emerging Markets, company has presences in Africa, Asia, Middle East, and CIS on broader therapeutic segments such as anti-malarial, gastro, antibiotics, cardiology, dermatology, pain management, etc. In USA, company has already no. of approved ANDA’s which are either commercialized or in process of being commercialized and large no. of ANDA’s are awaiting US FDA approval. We have state-of-the-art research facilities for formulation (finished product) and API development located at Mumbai, India. Our R&D capabilities are evident from number of products launched 1st to market by the company providing patients most needed compliance and convenience. A dedicated and focused team of more than 750 Ajantaites work for R&D, which is growing continuously. Ajanta has four formulations manufacturing facilities located in India and 1 in Mauritius. Besides that, we also have an API manufacturing facility located at Waluj, India. Ajanta’s flagship formulation facility at Paithan (Maharashtra, India) has approval of USFDA, WHO- Geneva (prequalification), UNICEF and many regulatory authorities from different parts of the world. We continuously invest in enhancing our existing manufacturing facilities to meet current cGMP requirements and also construct new facilities to meet the company’s growth requirements. We are in process of setting up 1 more formulations manufacturing facility for domestic and emerging markets at Guwahati, Assam. Please visit http://ajantapharma.com/ for more information. Contact: careers@ajantapharma.com
Specialties
Speciality Branded Generics, Generics, Complex Formulations
-
Website
-
Industry
Pharmaceuticals
-
Type
Public Company
-
Headquarters
98 Ajanta House Charkop, Kandivili West Mumbai,Maharashtra 400067 India
-
Company Size
5001-10,000 employees
-
Founded
1973
Rajesh Agrawal (left), Ajanta Pharma’s joint managing director, with brother Yogesh, who is also managing director of the company, at their Kandivli facility
Ajanta Pharma needed a shot of its own medicine, an energiser like 30-Plus. It found its antidote in the new generation of Agrawals: Mannalal’s sons, Yogesh and Rajesh.
“When I joined Ajanta (in 2000), and realised what was going on, I wanted to run away. I thought to myself, ‘Why did I return from the US? I could have had a job there,’” says Rajesh, 39, Ajanta’s joint managing director, who has a management degree from Bentley College, Massachusetts. “It was tough in the beginning, especially the situation with creditors and debtors.”
Together, Rajesh and his older brother Yogesh, 43, who is managing director, changed Ajanta’s trajectory by focusing on the ‘specialty’ generic drug market and putting an end to the company’s legacy businesses, which included OTC drug sales and supplying drugs to government health agencies in India and other countries.
This was a risky move, but it has paid off. Ajanta Pharma closed FY15 with a consolidated net sales of Rs 1,481 crore and a net profit of Rs 310 crore (this is a compound annual growth rate, or CAGR, of 57 percent for four years since 2011). In terms of net sales, it recorded a CAGR of 31 percent for the same period. This growth has come on a low base, but the signs are encouraging. Its market value currently stands at around Rs 13,500 crore; this is a 65-fold growth in 15 years.
References
https://www.linkedin.com/company/263285
/////////Ajanta Pharma, “One of the Giants of Tomorrow” , Fortune India, AWARD, Fortune India, RAJESH AGRAWAL
Glenmark bags two accolades at Pharmexcil Awards 2014
Glenmark bags two accolades at Pharmexcil Awards 2014
read
read at
http://www.glenmarkpharma.co.za/blog/glenmarks-bags-2-gold-accolades-at-pharmexcil-awards-2014
Glenmark conferred with Best Biotech New Molecular Entity Patent award
IDMA best biotech NEW MOLECULAR ENTITY patent award to Glenmark
YEAR 2012-2013 YEAR in Mumbai India
PATENT US 8236315
GLENMARK PHARMACEUTICALS, S.A., SWITZERLAND
INVENTORS
Elias Lazarides, Catherine Woods, Xiaomin Fan, Samuel Hou, Harald Mottl, Stanislas Blein, Martin BertschingerALSO PUBLISHED ASCA2712221A1, CN101932606A,EP2245069A1, US20090232804,WO2009093138A1
|
USPTO, USPTO Assignment, Espacenet, US 8236315
The present disclosure relates generally to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders. The humanized antibodies or binding fragments thereof specific for human vWF may comprise complementarity determining regions (CDRs) from a non-human antibody (e.g., mouse CDRs) and human framework regions.
The present disclosure provides a humanized antibody or binding fragment thereof specific for vWF that comprises a heavy chain variable region sequence as set forth in SEQ ID NO: 19 and a light chain variable region sequence as set forth in SEQ ID NO: 28 ……….. CONT
MR GLEN SALDANHA
MD , CEO GLENMARK
INDIAN DRUG MANUFACTURERS’ ASSOCIATION (IDMA)
102-B Poonam Chambers, Dr A B Road, Worli, Mumbai 400 018, INDIA
Tel : +91 – 22 – 24944625 / 24974308. Fax : ++91 – 22 – 24957023
email: ppr@idmaindia.com website : http://www.idma-assn.org
New Drug Approvals 